GlassScriptPhysician profile
Edmar M Lacay
NPI 1821248907
$976.82
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $120.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $421.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $237.82 | 2019-2020 | |
| Astellas Pharma US INC | $53.90 | 2019 | |
| Philips North America LLC | $53.45 | 2019 | |
| Amgen INC. | $43.36 | 2019 | |
| Merck Sharp & Dohme LLC | $43.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.32 | 2019 | |
| Lilly USA, LLC | $28.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $27.36 | 2019-2020 | |
| Abbvie INC. | $26.65 | 2019 | |
| Pfizer INC. | $11.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmar Lacay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.